CIK 0001701108
- Non-accelerated filer
- Smaller reporting company
Spero Therapeutics, Inc.
Sign in to watch- Ticker
- SPRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-242-1600
- Business address
- 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139
- Former names
- Spero Therapeutics, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $42,485
- in 1 filing
Net −$42,485. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-05 | Deshpande Milind Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 | ||
| 2019-06-05 | VINK PATRICK V.J.J. Director | Grant or award · Stock Option (right to buy) | +6,073 | 6,073 | ||
| 2019-03-29 | Smith Cynthia Director | Grant or award · Stock Option (right to buy) | +12,146 | 12,146 | ||
| 2019-01-02 | Parr Thomas R JR Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2019-01-02 | Melnick David A. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2019-01-02 | Larkin Cristina Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2019-01-02 | Sendek Joel Chief Financial Officer | Grant or award · Stock Option (Right to Buy | +65,000 | 65,000 | ||
| 2019-01-02 | Mahadevia Ankit CEO and President | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2018-09-21 | Pottage John C Jr Director | Grant or award · Stock Option (right to buy) | +12,146 | 12,146 | ||
| 2018-07-17 | GLAXOSMITHKLINE PLC 10% owner | Purchase | +80,000 | $12.50 | $1.0M | 1,934,006 |
| 2018-07-06 | Mahadevia Ankit | Exercise or conversion | +1,600 | $5.90 | $9K | 67,417 |
| 2018-07-06 | Mahadevia Ankit | Sale | −500 | $17.50 | $9K | 66,917 |
| 2018-07-06 | Mahadevia Ankit | Sale | −100 | $17.55 | $2K | 66,817 |
| 2018-07-06 | Mahadevia Ankit | Sale | −400 | $17.58 | $7K | 66,417 |
| 2018-07-06 | Mahadevia Ankit | Sale | −100 | $17.62 | $2K | 66,317 |
| 2018-07-06 | Mahadevia Ankit | Sale | −100 | $17.71 | $2K | 66,217 |
| 2018-07-06 | Mahadevia Ankit | Sale | −200 | $17.90 | $4K | 66,017 |
| 2018-07-06 | Mahadevia Ankit | Sale | −200 | $17.92 | $4K | 65,817 |
| 2018-07-06 | Mahadevia Ankit | Exercise or conversion · Stock Option (Right to Buy) | −1,600 | 118,888 | ||
| 2018-07-05 | Larkin Cristina Chief Operating Officer | Exercise or conversion | +4,000 | $5.90 | $24K | 5,500 |
Page 14 of 17 · 340 trades